NCT01230970View on ClinicalTrials.gov

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

BN83495

40mg tablet oral daily administration from Day 1 to Day 14.

Trial Locations (1)

1474

Akershus University Hospital, Lørenskog

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY